RAMM Pharma Corp. Announces Non-Brokered Private Placement and Intention to Commence Normal Course Issuer Bid
The proceeds from the Offering are expected to be used for working capital and general corporate purposes.
- The proceeds from the Offering are expected to be used for working capital and general corporate purposes.
- Ramm also announces its intention to commence a normal course issuer bid (the “NCIB”), under which it may purchase up to 5% of the current number of issued and outstanding Common Shares.
- The NCIB may commence on or about September 5, 2023 and shall expire on the 12-month anniversary of the effective date of the NCIB.
- The Company has implemented the NCIB should it view the market price for its Common Shares to not adequately reflect the value of the Company.